QUEENSBURY, N.Y.–LAWFUEL – Law News, Law Jobs Network –AngioDynamics, Inc. (Nasdaq:ANGO) today announced that U.S. District Judge Nathaniel M. Gorton has set March 12, 2007 as the start date for the jury trial in the Diomed patent litigation. The trial will be held in the Federal District Court in Boston, Massachusetts, and legal arguments are expected to last between two and three weeks.
In January 2004 Diomed, Inc., a subsidiary of Diomed Holdings, Inc., filed a lawsuit against AngioDynamics alleging patent infringement related to AngioDynamics’ VenaCure® product line. VenaCure is a laser system used for the treatment of severe varicose veins. The lawsuit involves a single U.S. patent, number 6,398,777, covering a specific method of endovascular laser treatment of varicose veins.
“We strongly believe that our VenaCure procedure is materially different from the procedure described and claimed in Diomed’s patent and does not include limitations that are at the heart of ‘777 patent claims. For this reason, we are very confident that the jury will find that we do not infringe the patent, and we look forward to a final resolution of this litigation,” commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics.
About VenaCure
The VenaCure endovascular laser venous system is a patient friendly, minimally invasive alternative for the treatment of severe varicose veins. The VenaCure procedure, which lasts about 45 minutes, offers patients an effective outpatient alternative to surgical ligation and vein stripping. The Company markets and sells the VenaCure laser system throughout the United States.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products. More information is available at www.angiodynamics.com.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company’s expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.
